Nov 20 (Reuters) - HOOKIPA Pharma Inc :
* HOOKIPA PHARMA INC - ON NOVEMBER 18, CO APPROVED A PLANTO REDUCE WORKFORCE BY APPROXIMATELY 80%
* HOOKIPA PHARMA - RESTRUCTURING PLAN TO BEGIN IN Q4 2024, COMPLETE BY H1 2025
* HOOKIPA PHARMA - TO PAUSE CLINICAL DEVELOPMENT IN ESEBA-VEC PROGRAM
* HOOKIPA PHARMA - EARLY TERMINATION OF HPV16+ TRIAL NOT DUE TO EFFICACY OR SAFETY
* HOOKIPA PHARMA INC: WILL FOCUS PRIMARILY ON PROGRESSING THE PHASE 1-READY HB-700 PROGRAM FOR THE TREATMENT OF KRAS MUTANT CANCERS
Source text: [ Further company coverage:
免責聲明:投資有風險,本文並非投資建議,以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請,作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考,不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證,投資者應自行研究並在投資前尋求專業建議。